Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Teva
Baxter
Johnson and Johnson
Queensland Health
QuintilesIMS
Daiichi Sankyo
Federal Trade Commission

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,254,328

« Back to Dashboard

Which drugs does patent 9,254,328 protect, and when does it expire?

Patent 9,254,328 protects TYGACIL and is included in one NDA.

This patent has twenty-six patent family members in twenty-four countries.
Summary for Patent: 9,254,328
Title:Tigecycline compositions and methods of preparation
Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Inventor(s): Fawzi; Mahdi B. (Morristown, NJ), Zhu; Tianmin (Monroe, NY), Shah; Syed M. (Delray Beach, FL)
Assignee: Wyeth LLC (New York, NY)
Application Number:14/604,924
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process;

Drugs Protected by US Patent 9,254,328

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv TYGACIL tigecycline POWDER;IV (INFUSION) 021821-001 Jun 15, 2005 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,254,328

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,694,078 Tigecycline compositions and methods of preparation ➤ Try a Free Trial
7,879,828 Tigecycline compositions and methods of preparation ➤ Try a Free Trial
8,975,242 Tigecycline compositions and methods of preparation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,254,328

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 053827 ➤ Try a Free Trial
Australia 2006223226 ➤ Try a Free Trial
Brazil PI0608464 ➤ Try a Free Trial
Canada 2602089 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
Fuji
Argus Health
Julphar
McKesson
US Department of Justice
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.